Toremifene (citrate)

CAT: 0804-HY-B0005-01Size: 100 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0005-01Size:100 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 μM and 2.6 μM, respectively[1][2].
CAS Number
[89778-27-8]
Product Name Alternative
Z-Toremifene (citrate) ; NK 622; FC-1157a
UNSPSC
12352005
Hazard Statement
H302, H318, H410
Target
Apoptosis; Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Apoptosis; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/toremifene-citrate.html
Purity
99.88
Solubility
DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL
Smiles
ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O
Molecular Formula
C32H36ClNO8
Molecular Weight
598.08
Precautions
H302, H318, H410
References & Citations
[1]Matthew R Smith, Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis.Rev Urol. 2005; 7 (Suppl 3) : S30-S35.|[2]Gauri J Sabnis, Luciana Macedo, Olga Goloubeva, Toremifene - Atamestane; Alone or In Combination: Predictions from the Preclinical Intratumoral Aromatase Model. J Steroid Biochem Mol Biol. 2008 January; 108 (1-2) : 1-7.|[3]Taneja SS, Morton R, Barnette G, Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013 Feb 10;31 (5) :523-9.|[4]Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|J Med Chem. 2020 Oct 8;63 (19) :11085-11099.|Viruses. 2021 Jun 28;13 (7) :1255.|bioRxiv. 2020 May.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Patent. US11696914.|Res Sq. 2020 Dec 31:rs.3.rs-100914.

Related Products

CatalogName
HY-B0005SToremifene-d6 (citrate)
HY-B0005A-01Toremifene
HY-B0005AS-01Toremifene-d6
HY-B0005S1Toremifene-d6 (hydrochloride)
HY-132501S-014’-Hydroxy Toremifene-d6
HY-132500S-01(E/Z) -4-Hydroxy Toremifene-d6
HY-145566AEnvonalkib (citrate)
HY-17599Piperazine (citrate)
HY-B0463-01Clomiphene (citrate)
HY-127141Cizolirtine (citrate)

Alternative Products

CatalogName
GP8497-250mgToremifene citrate
TRC-T547502-10MGToremifene-d6 Citrate
A10940-100Toremifene citrate 100mg
A10940-500Toremifene citrate 500mg
C08048-01Toremifene Citrate (NK 622)
MBS6098774-01Toremifene Citrate (2-[4-[(1Z)-4-Chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethylethanamine)
T8067-25Toremifene Citrate (2-[4-[ (1Z) -4-Chloro-1,2-diphenyl-1-butenyl]phenoxy]-N, N-dimethylethanamine)
RM-T151800-01Toremifene

Popular Products